APTITUDE HEALTH®

EPICS

CAR T and Bispecific Agents in Hematologic Malignancies

August 26 and 31, 2022

Report Contents

EPICS

Meeting Snapshot

EPICS

EPICS

VIRTUAL CLOSED-DOOR ROUNDTABLE

DATE:
August 26 and 31, 2022

DISEASE STATE AND DATA PRESENTATIONS by key experts

INSIGHTS REPORT including postmeeting analyses and actionable recommendations

PANEL: Key experts in lymphoma, leukemia, and myeloma

- 7 from North America
- 6 from Europe

DISEASE-SPECIFIC DISCUSSIONS on therapeutic advances and their application in clinical decision-making

Panel Consisting of 7 North American and 6 European Experts in Hematologic Malignancies

EPICS

Keith Stewart, MBChB, MBA
University Health Network

Peter Martin, MD
Weill Cornell Medicine

Jae Park, MD
Memorial Sloan Kettering Cancer Center

Daniel DeAngelo, MD, PhD
Dana-Farber Cancer Institute

Irene Ghobrial, MD
Dana-Farber Cancer Institute

Paolo Caimi, MD
Case Western Reserve University School of Medicine

CO-CHAIR:
Frederick Locke, MD
H. Lee Moffitt Cancer Center

CO-CHAIR:
Marie José Kersten, MD
Academic Medical Center

Mohamad Mohty, MD, PhD
Saint-Antoine Hospital and Sorbonne University

Paolo Corradini, MD
Fondazione IRCCS Istituto Nazionale dei Tumori

Olivier Tournilhac, MD, PhD
Clermont Auvergne University

Josep-Maria Ribera, MD, PhD
Hospital Germans Trias i Pujol

Pier Luigi Zinzani, MD, PhD
University of Bologna Institute of Hematology and Medical Oncology

APTITUDE HEALTH®

Meeting Agenda: Day 1 – Friday, August 26, 2022

EPICS

Time	Topic	Speaker/Moderator
15.00 – 15.10 (10 min)	Welcome and Introductions	Marie-Jose Kersten, MD
15.10 – 15.20 (10 min)	Update on CAR T in DLBCL	Paolo Caimi, MD
15.20 – 15.45 (25 min)	Key Questions and Topics for Discussion	Marie-Jose Kersten, MD
15.45 – 15.50 (5 min)	Summary of Key Takeaways: CAR T in DLBCL	Paolo Caimi, MD
15.50 – 16.00 (10 min)	Update on CAR T in Indolent NHL/MCL	Paolo Corradini, MD
16.00 – 16.25 (25 min)	Key Questions and Topics for Discussion	Marie-Jose Kersten, MD
16.25 – 16.30 (5 min)	Summary of Key Takeaways: CAR T in Indolent NHL/MCL	Paolo Corradini, MD
16.30 – 16.40 (10 min)	Update on Bispecific Antibodies in B-NHL	Peter Martin, MD
16.40 – 17.00 (20 min)	Key Questions and Topics for Discussion	Marie-Jose Kersten, MD
17.00 – 17.05 (5 min)	Summary of Key Takeaways: Bispecific Antibodies in B-NHL	Peter Martin, MD
17.05 – 17.15 (10 min)	Break	
17.15 – 17.25 (10 min)	Update on CAR T in Leukemias	Jae Park, MD
17.25 – 17.50 (25 min)	Key Questions and Topics for Discussion	Frederick Locke, MD
17.50 – 17.55 (5 min)	Summary of Key Takeaways: CAR T in Leukemias	Jae Park, MD
17.55 – 18.05 (10 min)	Update on Bispecific Antibodies in Leukemias	Josep-Maria Ribera, MD, PhD
18.05 – 18.20 (15 min)	Key Questions and Topics for Discussion	Frederick Locke, MD
18.20 – 18.25 (5 min)	Summary of Key Takeaways: Bispecific Antibodies in Leukemias	Josep-Maria Ribera, MD, PhD
18.25 – 18.30 (5 min)	Wrap-up and Overview of Day 2 Activities	Frederick Locke, MD

Meeting Agenda: Day 2 – Wednesday, August 31, 2022

EPICS

Time	Topic	Speaker/Moderator
16.30 – 16.35 (5 min)	Welcome and Introductions	Frederick Locke, MD
16.35 – 16.45 (10 min)	Update on CAR T in MM	Mohamad Mohty, MD, PhD
16.45 – 17.05 (20 min)	Key Questions and Topics for Discussion	Frederick Locke, MD
17.05 – 17.10 (5 min)	Summary of Key Takeaways: CAR T in MM	Mohamad Mohty, MD, PhD
17.10 – 17.20 (10 min)	Update on Bispecific Antibodies in MM	Keith Stewart, MBChB, MBA
17.20 – 17.40 (20 min)	Key Questions and Topics for Discussion	Frederick Locke, MD
17.40 – 17.45 (5 min)	Summary of Key Takeaways: Bispecific Antibodies in MM	Keith Stewart, MBChB, MBA
17.45 – 17.50 (5 min)	Break	
17.50 – 18.00 (10 min)	Impact of Real-world Data on CAR T-Cell Therapies and Bispecific Antibodies	Olivier Tournilhac, MD, PhD
18.00 – 18.20 (20 min)	Key Questions and Topics for Discussion	Marie-Jose Kersten, MD
18.20 – 18.25 (5 min)	Summary of Key Takeaways: Impact of Real-world Data on CAR T-Cell Therapies	Olivier Tournilhac, MD, PhD
18.25 – 18.35 (10 min)	Sharing Experiences: Current Barriers to Real-world CAR T Adoption in the US	Irene Ghobrial, MD
18.35 – 18.45 (10 min)	Sharing Experiences: Current Barriers to Real-world CAR T Adoption in Europe	Pier Luigi Zinzani, MD, PhD
18.45 – 19.15 (30 min)	Key Questions and Topics for Discussion	Marie-Jose Kersten, MD
19.15 – 19.25 (10 min)	Summary of Key Takeaways: Real-world CAR T Adoption	Irene Ghobrial, MD, and Pier Luigi Zinzani, MD, PhD
19.25 – 19.30 (5 min)	Closing Remarks	Marie-Jose Kersten, MD

APTITUDE HEALTH®

EPICS

Updates on CAR T Cells and Bispecific Agents

Updates on CAR T in DLBCL (1/2)

Presented by Paolo Caimi, MD

EPICS

CAR Ts are standard of care in DLBCL

> There are currently 3 approved CAR T-cell therapies for

CAR Ts are explored in earlier lines

> In the TRANSCEND trial, liso-cel showed 73% ORR and 53% CR with

Updates on CAR T in DLBCL (2/2)

Presented by Paolo Caimi, MD

EPICS

Ongoing research with autologous CAR T alternatives

> Dual CAR Ts (eg, CD19-CD22) are under

Update on CAR T in Indolent NHL/MCL

Presented by Paolo Corradini, MD

EPICS

CAR Ts are approved in FL and MZL

> Axi-cel is approved in FL and MZL on the basis of results

Optimal usage of CAR Ts in MCL is challenging

> Brexu-cel is approved for patients with relapsed/refractory MCL on the

Update on Bispecific Antibodies in B-NHL

Presented by Peter Martin, MD

EPICS

Bispecifics are close to approval in B-NHL

> Currently, the only approved bispecific T-cell engager

Overview of bispecific antibodies in B-NHL

	Blinatumomab	Epcoritamab	Mosunetuzumab	Odronextamab	Glofitamab	Plamotamab

CAR T Cells in Leukemias (1/2)

Presented by Jae Park, MD

EPICS

CAR Ts are in use in B-ALL

> There are currently 2 approved CD19-targeting CAR

Relapse after CAR T in ALL

> In adult ALL, most of the relapses after CAR Ts are CD19 positive, and in

CAR T Cells in Leukemias (2/2)

Presented by Jae Park, MD

EPICS

Optimizing CAR Ts in B-ALL

> Bispecifics with reduced toxicity profile are under

> CAR T development is challenging in AML due to the heterogeneity of

Update on Bispecific Antibodies in Leukemias

Presented by Josep-Maria Ribera, MD, PhD

EPICS

Blinatumomab is standard treatment in B-ALL

> Blinatumomab is the only approved agent in B-ALL and is

Prospects of combining bispecifics in ALL

Immunotherapy in Early Phases of Ph-neg ALL: Results From Phase II Trials

Update on CAR T in MM (1/2)

Presented by Mohamad Mohty, MD, PhD

EPICS

An overview of CAR T-cell therapies in MM

> In recent years, rapid

Alternative

Update on CAR T in MM (2/2)

Presented by Mohamad Mohty, MD, PhD

EPICS

Two CAR Ts are currently approved in MM

> Ide-cel was the first anti-BCMA CAR T-cell therapy approved for

Novel CAR T products on the horizon

> CART-ddBCMA is an autologous anti-BCMA CAR T-cell therapy

Update on Bispecific Antibodies in MM (1/2)

Presented by Keith Stewart, MBChB, MBA

EPICS

Teclistamab has become the first approved BCMA-targeting bispecific antibody

> Multiple bispecific antibodies have demonstrated promising durable responses in

STUDY POPULATION

OUTCOMES

EXPERT CONCLUSIONS

RESPONSE INDICATORS ACROSS ANALYSIS PERIODS

Update on Bispecific Antibodies in MM (2/2)

Presented by Keith Stewart, MBChB, MBA

EPICS

Novel bispecific antibodies for RRMM

BCMA-targeting bispecific antibodies under development

Impact of Real-world Data on CAR T-Cell Therapies and Bispecific Antibodies

Presented by Olivier Tournilhac, MD, PhD

EPICS

CAR T clinical trials are reproducible in the real world

> A real-world analysis of axi-cel in 298 DLBCL patients

Real-world data provide new information on CAR T usage

> A matched analysis showed higher activity and more toxicities with axi-

Sharing Experiences: Current Barriers to Real-world CAR T Adoption in the US

Presented by Keith Stewart, MBChB, MBA, on behalf of Irene Ghobrial, MD

EPICS

Consensus on MM patient selection for CAR T referral

> At the IMS 2022, a consensus statement was presented

Real-world challenges of CAR T usage in the US

> In the US, there are some challenges that require attention,

Sharing Experiences: Current Barriers to Real-world CAR T Adoption in Europe

Presented by Pier Luigi Zinzani, MD, PhD

EPICS

CAR T usage is increasing in Europe

> EBMT registry analysis shows CAR T usage increased

Sharing Experiences: Current Barriers to Real-world CAR T Adoption in Europe

Presented by Pier Luigi Zinzani, MD, PhD

EPICS

CAR T utilization is similar to HSCT

> A treatment utilization comparison of CAR T and HSCT

Strategies to improve CAR T outcomes

APTITUDE HEALTH®

EPICS

Key Insights

CAR T Cells in DLBCL (1/2)

EPICS

Experience with the currently approved 3 CAR Ts (axi-cel, tisa-cel, and liso-cel) for patients with relapsed/refractory DLBCL shows the importance

STUDY POPULATION

OUTCOME

EXPERT CONCLUSIONS



CAR T Cells in DLBCL (2/2)

EPICS

There is a need to further optimize CAR T application in DLBCL for broader usage in clinical practice. Community physicians and transplant

STUDY POPULATION

OUTCOME

EXPERT CONCLUSIONS

CAR T Cells in MCL and FL (1/2)

EPICS

In FL, axi-cel and tisa-cel show similar activity in matched cohorts, on the basis of an

CAR T Cells in MCL and FL (2/2)

EPICS

In MCL, brexu-cel is approved on the basis of outcomes of the ZUMA-2 trial. BTKi's are

Bispecific Agents in B-NHL

EPICS

Bispecifics show response rates comparable with CAR Ts, but current trials with bispecifics have shorter follow-up vs CAR Ts. There are multiple

STUDY POPULATION

OUTCOME

EXPERT CONCLUSIONS

CAR T Cells in Leukemias (1/2)

EPICS

There are 2 CAR Ts approved in the treatment of B-cell precursor

CAR Ts are expected to move to earlier lines, especially for patients

CAR T Cells in Leukemias (2/2)

EPICS

In AML, there are CAR Ts under clinical research, but CAR Ts seem to not

Bispecific Agents in Leukemias (1/2)

EPICS

Blinatumomab is an integrated part of ALL management in the released/refractory setting, and it is moving to earlier lines with the approval in

STUDY POPULATION

OUTCOME

EXPERT CONCLUSIONS

Bispecific Agents in Leukemias (2/2)

EPICS

Bispecifics in AML have shown promising activity in hard-to-treat

STUDY POPULATION

OUTCOME

EXPERT CONCLUSIONS

CAR T Cells in MM (1/2)

EPICS

Experts are excited about BCMA-targeting CAR Ts in MM since the approval of ide-cel and cilta-cel. There are 8 additional products in

STUDY POPULATION

OUTCOME

EXPERT CONCLUSIONS



CAR T Cells in MM (2/2)

EPICS

CAR T therapies require further optimization in MM to match current and future demands when CAR Ts would be available in earlier lines

Bispecific Agents in MM (1/2)

EPICS

Thera are multiple bispecifics under clinical development in earlier lines that recently showed promising activity in heavily pretreated patients, but

STUDY POPULATION

OUTCOME

EXPERT CONCLUSIONS

RESPONSE INDICATORS ACROSS ANALYSIS PERIODS

Bispecific Agents in MM (2/2)

EPICS

Treatment sequencing in MM is expected to become more complex with the availability

Impact of Real-world Data on CAR T-Cell Therapies and Bispecific Antibodies

EPICS

Real-world analysis may help tease out the differences between CAR Ts, as clinical trials in DLBCL with CAR T are vastly different

Current Barriers for Real-world CAR T Adoption

EPICS

Globally, there is a need to re-evaluate the reimbursement systems, as novel therapies have not only greatly improved patient outcomes, but also

STUDY POPULATION

OUTCOME

EXPERT CONCLUSIONS

Current Barriers for Real-world CAR T Adoption – North America

EPICS

In the US, CAR T therapies face similar challenges across indications in terms of referrals, timely manufacturing, costs, and insurance

Current Barriers for Real-world CAR T Adoption – Europe

EPICS

In Europe, barriers to CAR T usage greatly correspond to country-level accessibility and

APTITUDE HEALTH®

US Headquarters
5901-C Peachtree Dunwoody Road NE
Suite 200, Atlanta, GA 30328, US

EU Headquarters
Wilhelmina van Pruisenweg 104
2595 AN The Hague, the Netherlands

aptitudehealth.com